Loading
A phase 3 trial of osimertinib in lung cancer, run by Fudan University, not yet recruiting.
Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) is a phase 3, randomised interventional study registered as NCT06323148 by Fudan University, with a registry enrolment figure of 226 participants, started 2024-04-01 and due to reach its primary completion in 2026-03-31. Interventions recorded: Osimertinib; No adjuvant therapy. Conditions listed: Lung Cancer; EGFR Gene Mutation; Minimal Residual Disease. Primary outcome: The 3-year Disease-Free Survival (DFS) rate between the observation group and the osimertinib treatment group.. Lung eligibility wording from the registry: "Histologically confirmed diagnosis of non-small cell lung cancer". No results are recorded here; the registry entry is the source.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, MRD / molecular residual disease testing, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, MRD / molecular residual disease testing, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.